Immunocore Reaches Target Enrolment in Phase 3 TEBE-AM Melanoma Trial
Immunocore has reached its target enrolment of 540 patients in the Phase 3 TEBE-AM trial of KIMMTRAK in previously treated advanced melanoma. Topline overall survival data, the primary endpoint, are expected as early as the end of 2026.